Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States. The prognosis for patients with CRC varies widely, but new prognostic biomarkers provide the opportunity to implement a more individualized approach to treatment selection. To assess the cost-effectiveness of 3 therapeutic strategies, namely, endoscopic therapy (ET), laparoscopic colectomy (LC), and open colectomy (OC), for patients with T1 CRC with biomarker profiles that prognosticate varying levels of tumor progression in the US payer perspective. In this economic evaluation study, a Markov model was developed for the cost-effectiveness analysis. Risks of all-cause mortality and recurrent cancer after ET, LC, or OC were estimated with a 35-year time horizon. Quality of life was based on EuroQoL 5 Dimensions scores reported in the published literature. Hospital and treatment costs reflected Medicare reimbursement rates. Deterministic and probabilistic sensitivity analyses were performed. Data from patients with T1 CRC and 6 biomarker profiles that included adenomatous polyposis coli (APC), TP53 and/or KRAS, or BRAFV600E were used as inputs for the model. Data analyses were conducted from February 27, 2019, to May 13, 2019. En...Continue Reading
References
Jun 3, 1992·Journal of the National Cancer Institute·C M FreyL G Kessler
Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Oct 25, 1995·JAMA : the Journal of the American Medical Association
Oct 16, 1996·JAMA : the Journal of the American Medical Association·M C WeinsteinL B Russell
May 14, 2004·The New England Journal of Medicine·UNKNOWN Clinical Outcomes of Surgical Therapy Study GroupDavid Ota
Jul 5, 2005·The Lancet Oncology·Ruben VeldkampUNKNOWN COlon cancer Laparoscopic or Open Resection Study Group (COLOR)
Oct 17, 2006·Diseases of the Colon and Rectum·Timothy R WilsonP Kind
Jun 27, 2007·Gastrointestinal Endoscopy·Shinji TanakaKazuaki Chayama
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alberto MalesciArmando Santoro
Sep 26, 2007·Annals of Surgery·James FleshmanUNKNOWN Clinical Outcomes of Surgical Therapy Study Group
Nov 29, 2007·Journal of the National Cancer Institute·Liz Savage
Dec 19, 2009·The New England Journal of Medicine·Sanford D Markowitz, Monica M Bertagnolli
Mar 17, 2010·Gastroenterology·Sameer D SainiSandeep Vijan
Jun 9, 2010·Archives of Pathology & Laboratory Medicine·Giacomo PuppaGiuseppe Pelosi
Nov 26, 2010·Annual Review of Pathology·Eric R Fearon
Mar 27, 2012·Gastroenterology·Christian P PoxWolff Schmiegel
Jun 27, 2012·Cancer Causes & Control : CCC·Isabelle SoerjomataramLonneke V van de Poll-Franse
Sep 8, 2012·British Journal of Cancer·A KapidzicM E van Leerdam
May 3, 2013·Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society·Rajesh Kumar ParamasivamRungsun Rerknimitr
Jun 12, 2014·Gastrointestinal Endoscopy·Golo AhlenstielUNKNOWN Australian Colonic Endoscopic Mucosal Resection (ACE) Study Group
Jun 20, 2014·World Journal of Gastroenterology : WJG·Gemma BinefaManuel Medina-Hayas
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Dec 2, 2015·Molecular and Clinical Oncology·Zexian ChenPing Lan
Dec 23, 2015·International Journal of Colorectal Disease·Naoki AsayamaKazuaki Chayama
Feb 10, 2016·Gastrointestinal Endoscopy·Gottumukkala RajuJohn Stroehlein
Jun 16, 2016·Nature Communications·Michael J SchellTimothy J Yeatman
Aug 20, 2016·Health Economics Review·Kim Jeong, John Cairns
Feb 22, 2017·Gastrointestinal Endoscopy·Douglas K RexJohn M Dewitt
Apr 15, 2017·Gastrointestinal Endoscopy·Anne F PeeryIan S Grimm
Jun 15, 2017·JAMA Surgery·Kyle H SheetzJustin B Dimick
Oct 3, 2018·Gastrointestinal Endoscopy·Hao DangJurjen J Boonstra
Nov 5, 2019·Annals of Internal Medicine·Amir QaseemJanice Tufte